#1Dien CERTARA O Ⓡ Accelerating Medicines May 2022#2Disclaimer The following presentation has been prepared by Certara, Inc. ("we", "us", or "the Company") solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this document shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this document and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Forward-Looking Statements This document contains certain statements that constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, with respect to the future of the Company's industry and markets, customer partnerships, business performance, strategies and expectations. These statements typically contain words such as "believe," "may," "potential," "will," "plan," "could," "estimate," "expects" and "anticipates" or the negative of these words or other similar terms or expressions. Any statement in this document that is not a statement of historical fact is a forward-looking statement and involves significant risks and uncertainties. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. You should not rely upon forward-looking statements as predictions of future events and actual results, events, or circumstances. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the acceptance of model-informed biopharmaceutical discovery and development by regulators, actions by our competitors, changes in the regulatory or business environment of our customers, and the and the other factors detailed under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" and elsewhere in our Securities and Exchange Commission filings, and reports, including the Form 10-K filed with the SEC on March 15, 2021. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events. Factors that may materially affect our results and those risks listed in filings with the Securities and Exchange Commission. Neither the delivery of this document nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date. © Copyright 2022 Certara, Inc. All rights reserved. 2 CERTARA#3Our Mission We accelerate medicines to patients using biosimulation software, technology and services to transform traditional drug discovery and development. © Copyright 2022 Certara, Inc. All rights reserved. 3 CERTARA#4Certara at a Glance BUSINESS 20+ Year History of innovation 1,100+ Employees(1) 350+ with Ph.D.s, Pharm.D.s and M.D.s 16 Acquisitions Track record of accretive, complementary acquisitions (1) As of 12/31/2021 (2) Market research reports from Grand View and SpendEdge (3) Customer data as of 12/31/2021 (4) See Appendix for reconciliation tables © Copyright 2022 Certara, Inc. All rights reserved. ● ● ● END-TO-END PLATFORM Software ● Biosimulation Regulatory & compliance Market access Technology-Driven Services • Drug discovery & development with biosimulation • Regulatory science Market access $13B TAM growing at 12-16% CAGR(²) CUSTOMERS(3) 2,000+ Customers across 62 countries 10+ Year Average tenure for top 30 customers 299 customers with ACV > $100,000 (15% growth YoY) 1Q 2022 FINANCIALS $81.6M Revenue 22% YoY Growth (13% excl. Pinnacle 21) Net Income $2.2M PY $1.1M $27.7M Adjusted EBITDA(4) 16% YoY Growth 34% Adjusted EBITDA Margin 4 CERTARA#5Biosimulation is transforming traditional drug R&D ● Traditional R&D Pain Points On average, it takes more than 10 years and $2B to bring a drug to market¹ The probability of success of compounds entering Phase I trials is only 7%², and even in Phase III, just 53%³ of drugs reach the market ~70% of drugs that failed in Phase II or Phase III trials4 failed due to safety and efficacy issues 111 ● Benefits of Biosimulation In silico trials can replace human clinical trials in certain cases, saving significant time and money Biosimulation helps to increase probability of success in human clinical trials, the most expensive part of drug development Biosimulation helps to optimize dosing for different populations for enhanced safety and efficacy Biosimulation can deliver significant time and cost savings in drug discovery and development 1. Biopharmaceutical Research and Development: The Process Behind New Medicines. www.PhRMA.org, January 2012, Washington, US http://phrma-docs.phrma.org/sites/default/files/pdf/rd brochure 022307.pdf 2. Dowden, H. et al. Trends in clinical success rates and therapeutic focus. Nature Reviews Drug Discovery 18, 495-496 (2019) 3. EvaluatePharma. World Preview. 2020 4. Harrison, R. Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov 15, 817-818 (2016). https://doi.org/10.1038/nrd.2017.184 © Copyright 2022 Certara, Inc. All rights reserved. 5 CERTARA#6Biosimulation utilizes virtual patients to conduct in silico trials Biosimulation is the computer-aided mathematical modeling of biological processes and systems to simulate and predict how the body affects the drug and how the drug affects the body Simcyp Advanced Models for 10 Organs Skin Lung Liver Adipose Gut O ป SY © Copyright 2022 Certara, Inc. All rights reserved. ● Brain Heart Kidney Muscle Bone Biosimulation Software Applications First-in-Human Dosing Drug-Drug Interactions Clinical Study Design Bioequivalence Renal Impairment Reduced Cardiac Output Pediatric Dosing 6 Formulation Hepatic Impairment We have created 25 different virtual patient populations and mathematical models for 10 organs CERTARA Food Effect#7Growing industry and regulatory adoption of biosimulation Increased Incorporation of Biosimulation with FDA Guidance² ~2,000 2000 2001 Number of Scientific Publications on Biosimulation 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 PK Modeling PBPK 2014 2015 2016 2017 2018 2019 ~8,000 2020 2021 YTD PopPK 3 Dose-response <2000 1. Science Direct search for publications by key search terms 2. Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations. Wang et al. Clinical Pharmacology and Therapeutics, April 2019 © Copyright 2022 Certara, Inc. All rights reserved. 30+ FDA Guidances to Date 5 Renal impairment Hepatic impairment 2000 - 2010 6 Pediatric HIV Animal QT interval prolongation 2011-2015 7 17 Pediatric rare diseases Drug-drug interaction PBPK Biosimilars Hypertension Ulcerative colitis Multi-regional clinical trials 2016-2020 CERTARA#8Simcyp software has informed 250+ labels for 90 novel drug approvals Tibsovo (ivosidenib) Blincyto (blinatumomab) Alunbrig (brigatinib) Iclusig (ponatinib) Calquence (acalabrutinib) Lynparza (olaparib) Tagrisso (osimertinib) Brukinsa (zanubrutinib) Ayvakit (avapritinib) Inrebic (fedratinib hydrochloride) Turalio (pexidartinib) Lenvima (lenvatinib) Tepmetko (tepotinib hydrochloride) Genentech Genentech Genentech Genentech Incyte Janssen Janssen ASSO ooo ONCOLOGY RARE DISEASE CENTRAL NERVOUS SYSTEM INFECTIOUS DISEASE GASTROENTEROLOGY CARDIOVASCULAR OTHER Agios Amgen Ariad Ariad (Takeda) AstraZeneca AstraZeneca AstraZeneca Beigene BluePrint Medicines Celgene Daiichi Sankyo Eisai EMD Serono AkaRx (Eisai) AstraZeneca Auriana Genentech Genentech AbbVie AbbVie Alkermes Alkermes Gilead GSK Janssen Merck AstraZeneca Helsinn Actelion (J & J) AbbVie Galderma Doptelet (avatrombopag maleate) Koselugo (selumetinib) Lupkynis (voclosporin) Enspryng (satralizumab) Evrysdi (risdiplam) Rinvoq (upadacitinib) Qulipta (atogepant) Aristada (aripiprazole lauroxil) Lybalvi (olanzapine; samidorphan) Veklury (remdesivir) Dectova (zanamivir) Olysio (simeprevir) Pifeltro (doravirine) Movantik (naloxegol) Akynzeo (fosnetupitant/palonosetron) Opsumit (macitentan) Orilissa (elagolix) Aklief (trifarotene) Lilly Lilly Loxo Oncology Novartis Novartis Novartis Global Blood Therapeutics Intercept Kadman Merck Mirum Eisai GW Research Janssen Kyowa Kirin Merck Nabriva Novartis Shionogi Johnson & Johnson Alecensa (alectinib) Novartis Cotellic (cobimetinib) Novartis Polivy (polatuzumab vedotin-piiq) Novartis Rozlytrek (entrectinib) Novartis Pemazyre (pemigatinib) Novartis Balversa (erdafitinib) Pfizer Erleada (apalutamide) Pfizer Retevmo (selpercatinib) Pharmacyclics Verzenio (abemaciclib) Sanofi Vitrakvi (larotrectinib) Seattle Genetics Farydak (panobinostat) Spectrum Kisqali (ribociclib succinate) Takeda Scemblix (asciminib) Verastem Janssen Lilly Oxbryta (voxelotor) Ocaliva (obeticholic acid) Rezurock (belumosudil) Welireg (belzutifan) Livmarli (maralixiba) Dayvigo (lemborexant) Epidiolex (cannabidiol) Ponvory (ponesimod) Nourianz (istradefylline) Prevymis (letermovir) Xenleta (lefamulin acetate) Egaten (triclabendazole) Symproic (naldemedine) Xarelto (rivaroxaban) Invokana (canagliflozin) Olumiant (baricitinib) Novartis PTC Therapeutics Sanofi Genzyme Vertex Vertex Lilly Novartis UCB Tibotec VIIV VIIV Shire Pfizer Merck Odomzo (sonidegib) Piqray (alpelisib) Rydapt (midostaurin) Tabrecta (capmatinib) Zykadia (ceritinib) Bosulif (bosutinib) Lorbrena (lorlatinib) Imbruvica (ibrutinib) Jevtana (cabazitaxel) Tukysa (tucatinib) Beleodaq (tucatinib) Exkivity (mobocertinib) Copiktra (duvelisib) Isturisa (osilodrostat) Emflaza (deflazacort) Cerdelga (eliglustat tartrate) Symdeko (tezacaftor/ivacaftor) Trikafta (elexacaftor/ivacaftor/tezacaftor) Reyvow (lasmiditan succinate) Mayzent (siponimod fumaric acid) Briviact (brivaracetam) Edurant (rilpivirine) Cabenuva Kit (cabotegravir, rilpivirine) Vocabria (cabotegravir sodium) Motegrity (prucalopride) Revatio (sildenafil) Steglatro (ertugliflozin) We believe that our customers would have faced millions in additional costs and significant launch delays had they conducted human clinical trials for these drug label claims#9Blue chip customer base spanning large biopharma and biotech Eisai Abbott Pfizer ARVINAS (Incyte) Otsuka CHEST Select Customers astellas gsk Lundbeck SANOFI AstraZeneca biohaven clarus GALDERMA Opharmaceuticals THERAPEUTICS © Copyright 2022 Certara, Inc. All rights reserved. Lilly Medicines Development for Global Health SHIONOGI INC. Sumitomo Dainippon VERTEX Pharma Mitsubishi Tanabe Pharma GRUNENTHAL Biogen MERCK TAISHO PHARMACEUTICAL NEKTAR idorsia ono ucb Number of FDA Approvals Since 2014 Orphan designation Oncology Infectious disease Neurology Hematology Dermatology Cardiology Gastroenterology Pulmonary Diabetes Migraine Psychiatry Sleep disorders Bone Other 0 20 90% of novel drug approvals were achieved by our customers 40 60 80 Number of Drug Approvals *Excludes diagnostics Orphan designation applies across therapeutic areas We have more than 2,000 customers worldwide across 62 countries, including 38 of the top 40 biopharmaceutical companies by R&D spend in 2020 100 9 120 140 CERTARA#10The Certara End-to-End Platform Software Tech-driven Services 1. As of 12/31/2021 Discovery 30% of revenue¹ 70% of revenue¹ Preclinical Clinical Across All Drug Types (NDAs and BLAS) Biosimulation Software Platforms © Copyright 2022 Certara, Inc. All rights reserved. Regulatory and Compliance Software Market Access Software Drug Discovery and Development Services with Biosimulation Regulatory Science Post-Approval Market Access For over 20 years, we have purpose-built and invested in our proprietary end-to-end platform with strategic acquisitions and innovation 10 CERTARA#11Our end markets are large and growing Biosimulation $2.8B+ Regulatory Science $8.8B+ Market Access $1.5B+ 12% -16% CAGR $13B+ TAM Today CAGR ~16% ~12% ~12% $21B+ 2026 TAM • Drastic need for digital transformation in $212B biopharma R&D market¹ • Industry is in paradigm shift, with biosimulation adoption accelerating and increasing acceptance from regulatory agencies ● Technology and analytics-driven improvements continue to grow exponentially in Life Sciences We use biosimulation and technology throughout R&D to reduce costs and improve outcomes 1. As of 2021 Sources: Grand View Research, SpendEdge © Copyright 2022 Certara, Inc. All rights reserved. 11 CERTARA#12Biosimulation TAM Segmentation Certara Solutions (illustrative examples) Biosimulation Software ~50% Scientists at global pharmaceutical companies, mid-tier pharma, biotechs and CROS Drug Discovery ~45% Quantitative Systems Pharmacology (QSP) o Immuno-oncology QSP o Immunogenicity QSP • Discovery Informatics o D360 Software © Copyright 2022 Certara, Inc. All rights reserved. ● ● ● Biosimulation TAM $2.8B Drug Development ~55% PBPK¹ o Simcyp Simulator PK/PD² o Phoenix Software Model-based meta-analysis o CODEX Databases 1 Physiologically-based pharmacokinetic (PBPK) 2 Pharmacokinetic/pharmacodynamic (PK/PD) Drug Discovery ~20% QSP Consulting ● ● Biosimulation Services ~50% Drug R&D programs Drug Development ~80% PBPK Consulting PK/PD analysis Model-based meta-analysis 12 CERTARA#13Differentiated scientific and technology expertise Key Differentiators Industry standard built over 20 years Adopted by 17 global regulatory agencies Embedded in customers' R&D processes - 90%+ renewal rate Validated by 34k+ scientific publications Used by ~400 academic institutions 10+ year average tenure for top 30 customers 1. Listed on Euronext Paris Exchange Software © Copyright 2022 Certara, Inc. All rights reserved. Tech-driven Services Scalable service model powered by proprietary technology ✓ High net revenue repeat rate of 108% in 2021 ✓ Integrated services with 90% of our top 50 customers using both biosimulation solutions and regulatory & access services ✓ Renowned for key opinion leadership ✓ Depth and breadth of experience across every therapeutic area and modality Our differentiated strengths enable us to win new customers and projects 13 CERTARA#14Deeply experienced leadership team and global talent footprint ~350 Scientists ~250 ~100 ~150 Regulatory Experts Market Access Specialists Software Developers & Technologists North America © Copyright 2022 Certara, Inc. All rights reserved. ~550 Europe ~400 Asia Pac Of our 1,100+ employees, 350+ hold PhD, PharmD, or MD degrees ~175 14 CERTARA#15Certara's Industry-Standard Software sim CYP Leading mechanistic biosimulation platform used to predict how drugs work, without human or animal studies D360 Biosimulation Integrated informatics platform with self-service access and analytics to help manage discovery projects All statistics are as of 12/31/2021 unless noted © Copyright 2022 Certara, Inc. All rights reserved. P Phoenix Industry-leading software for PK/PD, toxico-kinetic, and non-compartmental analyses required for regulatory submissions - 55 proprietary databases for meta- analysis of a new drug's safety and CODEX efficacy relative to other products Certara Integral Repository Regulatory & Market Access H GlobalSubmit BaseCase PINNACLE 21 Our industry-leading software is adopted by more than 60,000 users worldwide across 62 countries CERTARA Synchrogenix™ Writer Cloud-based software to manage regulatory compliance and submissions and value communication 15#16Certara's platform is built to meet clients where they are Customer Journey Biotech $ Tangible cost and time savings drive renewal and retention © Copyright 2022 Certara, Inc. All rights reserved. First Landing Innovate Deeper Adoption Time Cross-Sell Large Biopharma Generates new biosimulation use case for novel therapy Adopts regulatory software to aid submission Increases licenses to expand use across drug programs; adopts additional biosimulation modules Licenses biosimulation software Retains services for expansion of indications Partners to develop and execute on regulatory strategy Licenses software for additional development projects Uses services to conduct biosimulation project 16 CERTARA#17Our R&D framework advances innovation in biosimulation ● ● ● ● © Copyright 2022 Certara, Inc. All rights reserved. ● Consortia collaboration User group meetings Scientific Advisory Board 1,000+ scientific customer projects per year Collaboration with 120+ academic institutions 5,000+ peer-reviewed articles 34,000 Google Scholar citations Scientific Research Customer Centricity Innovation Data Collection & Curation ● Regulatory Alignment ● Regulatory guidances Regulatory workshops Regulatory meetings for customer programs 25 virtual populations 18,000+ peer-reviewed manuscripts 8,000+ studies in our databases We have a regular cadence of incremental and breakthrough innovations with 10 new software applications and updates in 2021 17 CERTARA#18Our proven growth strategy Innovation Technology leader with 90%+ renewal rate © Copyright 2022 Certara, Inc. All rights reserved. Land and Expand Significant white space to expand with customers and add new ones M&A 16 successful strategic acquisitions, 11 with software Global Expansion People An employer of choice, attracting leading experts Track record of mid-teens topline growth with EBITDA margins in mid- to high-30s 18 CERTARA#19Long history of innovation driven by investment in our platform I 10 new software applications i | and updates in 2021 1 Regulatory Milestones Product Innovation FDA CRADA for veterinary drug development Phoenix v1.3 2012 Sim CYP Drug comes off FDA safety hold using biosim. Simcyp Cardiac Safety Simulator 2013 I I © Copyright 2022 Certara, Inc. All rights reserved. I I Great Lakes Brug Development, Inc. "Bridging the Gap in Drug Development" ● ● FDA grant for Simcyp dermal model Orphan drug DDI study waived using biosim. Launch of Pre-clinical Safety Store 2014 synchrogenix formulation approval isolely using PBPK I Alt. I | Virtual monkey for in silico animal testing 2015 ClinGenuity G Quantitative Solutions XenologiQ I I FDA grant for supersaturat ing drugs Phoenix PK/PD CoEs in China and Japan 2016 I I | First gene I I I I therapy eCTD submission • First immuno- genicity QSP consortium ● 2017 I d3 MEDICINE Global Submit GlobalSubmit I Two FDA grants for virtual bioequivalence i • D360 I Reg. mechanistic ! • First immuno- modeling oncology QSP workshops incorporating biologics I I consortium 2018 ! First FDA i complex i generic virtual i bioequiv. approval BASECASE LASER ANALYTICA I PIRANA Certara Integral Data Repository 2019 I ! Acne drug I approval without i pediatric testing I I Covidpharma- I cology.com launch ! Launched Version 25+ COVID-19 programs 2020 ! Majority of new i FDA drug I i approvals used our I end-to-end platform YTD ISB 200 19 i I I I I IN SILICO BIOSCIENCES 21 of Simcyp PBPK Simulator author Well-positioned to continue delivering growth through organic and inorganic opportunities 2021 MEDICAL WRITING Insight PINNACLE²¹ CERTARA#20Certara Financial Highlights Predictable bookings drive substantial revenue growth $ Highly recurring revenue driven by strong renewal rates supports significant © Copyright 2022 Certara, Inc. All rights reserved. Robust margins with attractive free cash flow conversion Investment in platform to drive future growth opportunities Long term potential for accelerated adoption of biosimulation solutions 20 CERTARA#21Our Business Models Products Contract Type Contract Term Recurring Revenue¹ % of Revenue¹ 1. Data as of 12/31/2021 © Copyright 2022 Certara, Inc. All rights reserved. ● ● Simcyp Phoenix D360 CODEX Software ● GlobalSubmit BaseCase Pinnacle 21 Integral Individual or bundled licenses depending on customer 1-3 years Aggregate Renewal Rate 92% 30% ● ● Tech-Driven Services Biosimulation Regulatory Science Master Services Agreement or project specific Project and program dependent Market Access Net Revenue Repeat Rate 108% 70% 21 CERTARA#22Environmental, Social, and Governance (ESG) CERTARA INNOVATING TO IMPROVE LIVES CERTARA 2021 SUSTAINABILITY REPORT $28.1M 10 2021 R&D SPEND (10% OF REVENUE) top 25% IN ENGAGEMENT EMPLOYEE NET PROMOTER SCORE AMONG LIFE SCIENCE COMPANIES IN 2021 © Copyright 2022 Certara, Inc. All rights reserved. NEW PRODUCTS AND PRODUCT UPDATES IN 2021 ● 150+ SCIENTIFIC PUBLICATIONS, POSTERS AND PRESENTATIONS IN 2021 ● Certara Inaugural ESG Report Launched April 2022 Accelerating crucial medicines to patients Advancing scientific thought leadership and knowledge sharing Increasing engagement with employees 1,200+ 250+ DRUG PROGRAMS ADVANCED IN 2021 REGULATORY SUBMISSIONS IN THE PAST 4 YEARS 3,000+ SCIENTISTS TRAINED IN OUR SOFTWARE IN 2021 GENDER AND ETHNICALLY DIVERSE REPRESENTATION GLOBAL FEMALE TALENT REPRESENTATION FEMALE EMPLOYEES FEMALE MANAGERS AND ABOVE FEMALE NEW EMPLOYEE HIRES U.S. ETHNICALLY DIVERSE TALENT REPRESENTATION ETHNICALLY DIVERSE ETHNICALLY DIVERSE MANAGERS AND ABOVE ETHNICALLY DIVERSE NEW EMPLOYEE HIRES FY20 52% 46% 55% FY20 27% 22% 34% FY21 54% 48% 60% FY21 28% 22% 35%#23We have a deeply experienced leadership team William F. Feehery, PhD Chief Executive Officer QU PONT BCG West Jaap Mandema, PhD Chief Innovation Officer Pharsight alza © Copyright 2022 Certara, Inc. All rights reserved. Andrew Schemick Chief Financial Officer HAIGHTS CROSS COMMUNICATIONS KAPLAN ARTHUR ANDERSEN Leif E. Pedersen President, Software 35: SIEMENS ORACLE DASSAULT SYSTEMES Robert Aspbury, PhD President, Simcyp™ COVANCE. Amin Rostami, PhD Chief Scientific Officer Sim CYP MANCHESTER 1824 This neoyo wamesem Jieun W. Choe Chief Strategy & Marketing Officer triumphlearning™ Bosonic KAPLAN Nicolette Sherman Chief Human Resources Officer POINT SANOFI Ron DiSantis SVP, Corporate Development க் Roche IQVIA VISHAY Patrick F. Smith President, Integrated Drug Development 20 Richard M. Traynor General Counsel EDGE Therapeutics, Inc. Justin Edge President, Regulatory & Access Jenkens& Gilchrist GFK LifeCell AND Company PORZIO BROMBERO&NEWMAN PC. 23 Drayton T. Virkler Chief Commercial Officer IQVIA Talecris gsk BIOTHERAPEUTICS CERTARA#24Certara investment highlights $ Attractive end markets growing in mid-teens driven by R&D efficiency demand and global adoption EX Technology leader with highly predictable business model with 90%+ renewal rates Deeply embedded scientific solutions at the core of R&D with 2,000+ customers Significant opportunities to expand within customer base and add new customers worldwide Proven track record of innovation and 16 successful strategic acquisitions Long track record of growth and profitability with 35% + EBITDA margins and strong free cash flow © Copyright 2022 Certara, Inc. All rights reserved. 24 CERTARA#25Covering Analysts Bank Baird Bank of America Barclays Jefferies Morgan Stanley William Blair © Copyright 2022 Certara, Inc. All rights reserved. Analyst Vikram Kesavabhotla Michael Ryskin Luke Sergott David Windley Vikram Purohit John Kreger 25 CERTARA#26Dien CERTARA O Ⓡ Accelerating Medicines#27Reconciliation of Net Income (Loss) to Adjusted EBITDA Net income (a) Interest expense(a) Interest income (a) Provision for income taxes(a) Depreciation and amortization expense(a) Intangible asset amortization(a) Currency (gain) loss (a) Equity-based compensation expense(b) Acquisition-related expenses(d) Transaction-related expenses(e) Loss on disposal of fixed assets(f) First-year Sarbanes-Oxley implementation costs(g) Adjusted EBITDA © Copyright 2022 Certara, Inc. All rights reserved. THREE MONTHS ENDED MARCH 31 2021 $ $ 2022 (in thousands) $ 2.210 3,228 (11) 1,536 482 12,450 (705) 7,513 272 17 5 653 27,650 27 1,052 3,928 (70) 527 602 10,102 191 5,151 1,596 685 107 23,871 CERTARA#28Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) Net income(a) Currency gain (loss)(a) Equity-based compensation expense(b) Amortization of acquisition-related intangible assets (c) Acquisition-related expenses(d) Transaction-related expenses(e) Loss on disposal of fixed assets(f) First-year Sarbanes-Oxley implementation costs (8) Income tax expense impact of adjustments(h) Adjusted Net Income © Copyright 2022 Certara, Inc. All rights reserved. THREE MONTHS ENDED MARCH 31 2021 $ 2022 (in thousands) 2,210 $ (705) 7,513 10,880 272 17 5 653 (3,916) 16,929 28 $ 1,052 191 5,151 8,428 1,596 685 107 (2,786) 14,424 CERTARA#29Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Net income (a) Currency gain (loss)(a) Equity-based compensation expense (b) Amortization of acquisition-related intangible assets (c) Acquisition-related expenses(d) Transaction-related expenses(e) Loss on disposal of fixed assets(f) First-year Sarbanes-Oxley implementation costs (g) Income tax expense impact of adjustments(h) Adjusted Diluted Earnings Per Share Diluted weighted average common shares outstanding Effect of potentially dilutive shares outstanding (¹) Diluted weighted average common shares outstanding © Copyright 2022 Certara, Inc. All rights reserved. THREE MONTHS ENDED MARCH 31 2021 $ 2022 0.01 0.05 0.07 (0.02) 0.11 155,936,953 3,223,368 159,160,321 $ 29 0.01 0.03 0.06 0.01 (0.02) 0.09 147,160,084 4,924,661 152,084,745 CERTARA#30Notes to Reconciliations (a) Represents amounts as determined under GAAP. (b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy. (c) Represents amortization costs associated with acquired intangible assets in connection with business acquisitions. (d) Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions. (e) Represents costs associated with our public offerings that are not capitalized. (f) Represents the gain/loss related to disposal of fixed assets. (g) Represents the first-year Sarbanes-Oxley costs for accounting and consulting fees related to the Company's preparation to comply with Section 404 of the Sarbanes-Oxley Act in 2021. (h) Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction. (i) Represents potentially dilutive shares that were excluded from the Company's GAAP diluted weighted average common shares outstanding because the Company had a reported net loss and therefore including these shares would have been anti-dilutive. © Copyright 2022 Certara, Inc. All rights reserved. 30 CERTARA